Volume 22 Issue 3
Mar.  2024
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2024  >  22(3): 402-406
LU Changqing, HU Ting, SU Fang, WANG Zishu. Efficacy of apatinib combination in second-line treatment of advanced gastric cancer[J]. Chinese Journal of General Practice, 2024, 22(3): 402-406. doi: 10.16766/j.cnki.issn.1674-4152.003412
Citation: LU Changqing, HU Ting, SU Fang, WANG Zishu. Efficacy of apatinib combination in second-line treatment of advanced gastric cancer[J]. Chinese Journal of General Practice, 2024, 22(3): 402-406. doi: 10.16766/j.cnki.issn.1674-4152.003412
shu

Efficacy of apatinib combination in second-line treatment of advanced gastric cancer

doi: 10.16766/j.cnki.issn.1674-4152.003412
  • 1.

    Department of Medical Oncology, the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, China

Funds:

 KJ2019A0329

 202204295107020038

  • Received Date: 2023-04-05
    Available Online: 2024-05-27
    Abstract
  •   Objective  To retrospectively analyze the adverse effects and efficacy of apatinib monotherapy, combination chemotherapy, or immune second-line treatment for advanced gastric cancer, and to explore the factors that influence treatment efficacy.  Methods  The study involved 145 patients with advanced gastric cancer who were admitted to the First Affiliated Hospital of Bengbu Medical University between January 2015 and December 2020.The patients were divided into three groups based on their medication regimen: apatinib single-agent group (n=36), combination chemotherapy group (n=94) and combination immunization group (n=15). The effectiveness of the three second-line treatments for advanced gastric cancer was compared using the Kaplan-Meier method. The study employed a Cox regression model to analyze the factors that impact treatment efficacy. The study employed a Cox regression model to analyze the factors that impact treatment efficacy.  Results  In the second-line treatment of advanced gastric cancer. The combination chemotherapy and combined immunization group showed significantly higher median progression-free survival (mPFS) and median overall survival (mOS) compared to the apatinib monotherapy group (mPFS, 8.3 months vs. 3.6 months, P < 0.001; 8.4 months vs. 3.6 months, P=0.003; mOS, 11.0 months vs. 7.5 months, P < 0.001; 14.0 months vs. 7.5 months, P < 0.001). The objective response rates (ORRs) for the three treatments were 5.56%, 18.09% and 26.67% (P=0.097), respectively. The disease control rates (DCRs) were 19.44%, 37.23% and 33.33% (P=0.151), respectively. However, the differences were not statistically significant (P > 0.05). The incidence of grade Ⅲ-Ⅳ adverse reactions among the three treatment options was 22.2% (8/36), 19.1%(18/94) and 26.7% (4/15), respectively, and the difference was not statistically significant (P=0.863). The statistical analysis revealed that there was a significant correlation between the ECOG score, peritoneal metastasis, and combination and progression-free survival in patients (P < 0.001).  Conclusion  In the second-line treatment of advanced gastric cancer, combining apatinib with chemotherapy or immunotherapy can lead to better efficacy while maintaining reliable safety.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    吴伟霞. 阿帕替尼联合化疗用于晚期胃癌的临床疗效及生存分析[J]. 系统医学, 2020, 5(13): 106-108. https://www.cnki.com.cn/Article/CJFDTOTAL-XTYX202013039.htm

    WU W X. Clinical efficacy and survival analysis of apatinib and combined chemotherapy in advanced gastric cancer[J]. System med, 2020, 5(13): 106-108. https://www.cnki.com.cn/Article/CJFDTOTAL-XTYX202013039.htm
    [2]
    董芊汝. 替吉奥联合阿帕替尼一线治疗晚期胃癌的临床疗效及不良反应探讨[J]. 中国现代药物应用, 2019, 13(21): 1-3. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWYY201921002.htm

    DONG Q R. Clinical efficacy and adverse effects of tigio and apatinib in first-line treatment of advanced gastric cancer[J]. Modern drug application in China, 2019, 13(21): 1-3. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWYY201921002.htm
    [3]
    方科, 张战民. 白蛋白结合型紫杉醇联合替吉奥一线治疗晚期胃癌的回顾性分析[J]. 中国医学创新, 2020, 17(7): 40-44. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYCX202007011.htm

    FANG K, ZHANG Z M. Retrospective analysis of albumin-bound paclitaxel and tigiol for first-line treatment of advanced gastric cancer[J]. Chinese med innovation, 2020, 17(7): 40-44. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYCX202007011.htm
    [4]
    郑潇豪, 解亦斌. 中国晚期胃癌的诊疗现状[J]. 癌症进展, 2019, 17(1): 13-19, 48. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ201901004.htm

    ZHENG X H, XIE Y B. Current situation of the diagnosis and treatment of advanced gastric cancer in China[J]. Cancer progression, 2019, 17(1): 13-19, 48. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ201901004.htm
    [5]
    PARK S, NAM C M, KIM S G, et al. Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: a systematic review with Bayesian network meta-analysis[J]. Eur J Cancer, 2021, 144(6): 49-60.
    [6]
    钱江, 傅仲学. 胃癌抗血管生成治疗进展[J]. 现代医药卫生, 2019, 35(22): 3501-3503.

    QIAN J. Advances in antiangiogenic therapy for gastric cancer[J]. Modern medicine and health, 2019, 35(22): 3501-3503.
    [7]
    黄一波, 王国平, 王奕, 等. 胃癌患者SFRP1, SFRP2, SDC-2甲基化与病理特征的相关性分析[J]. 中华全科医学, 2021, 19(12): 2008-2011. doi: 10.16766/j.cnki.issn.1674-4152.002222

    HUANG Y B, WANG G P, WANG Y, et al. Correlation analysis of SFRP1, SFRP2 and SDC-2 methylation and pathological features in patients with gastric cancer[J]. Chinese Journal of General Practice, 2022, 19(12): 2008-2011. doi: 10.16766/j.cnki.issn.1674-4152.002222
    [8]
    MOK S, DUFFY C R, ANANG N, et al. Abstract A205: Effects of anti-CTLA-4 and anti-PD-1 on memory T-cell differentiation and resistance to tumor relapse[C]//Abstracts: Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, New York, 2018.
    [9]
    WEI Q, YUAN X, LI J, et al. PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study[J]. Transl Cancer Res, 2020, 9(9): 5315-5322. doi: 10.21037/tcr-20-1333
    [10]
    GUO Y, TANG J, HUANG X E, et al. Efficacy and toxicity of apatinib combined with or without chemotherapy for patients with advanced or metastatic chemotherapy-refractory gastric adenocarcinoma: a prospective clinical study[J]. Medicine, 2019, 98(6): e13908. DOI: 10.1097/MD.0000000000013908.
    [11]
    FUKUOKA S, HARA H, TAKAHASHI N, et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ⅰb trial (REGONIVO, EPOC1603)[J]. J Clin Oncol, 2020, 38(18): 2053-2066. doi: 10.1200/JCO.19.03296
    [12]
    邵闪闪, 徐峰. 卡瑞利珠单抗联合阿帕替尼治疗晚期胃癌17例临床观察[J]. 山东医药, 2021, 61(30): 46-48. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYY202130009.htm

    SHAO S S, XU F. Carrelizumab and apatinib in 17 patients with advanced gastric cancer[J]. Shandong medicine, 2021, 61(30): 46-48. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYY202130009.htm
    [13]
    殷国庆, 王忠, 周峰, 等. 阿帕替尼辅助标准化疗对晚期胃癌合并肝转移病人疗效及安全性的影响[J]. 安徽医药, 2020, 24(8): 1628-1631. https://www.cnki.com.cn/Article/CJFDTOTAL-AHYY202008043.htm

    YIN G Q, WANG Z, ZHOU F, et al. Influence of apatinib combined with standard chemotherapy on clinical efficacy and safety of patients with advanced gastric cancer combined with liver metastasis[J]. Anhui Medical and Pharmaceutical Journal, 2020, 24(8): 1628-1631. https://www.cnki.com.cn/Article/CJFDTOTAL-AHYY202008043.htm
    [14]
    TYCZYNSKA M, KEDZIERAWSKI P, KARAKUAL K, et al. Treatment strategies of gastric cancer-molecular targets for anti-angiogenic therapy: a state-of-the-art review[J]. J Gastrointest Cancer, 2021, 52(2): 476-488. doi: 10.1007/s12029-021-00629-7
    [15]
    MERIC-BERNSTAM F, LARKIN J, TABERNERO J, et al. Enhancing anti-tumour efficacy with immunotherapy combinations[J]. Lancet, 2021, 397(10278): 1010-1022. doi: 10.1016/S0140-6736(20)32598-8
    [16]
    唐敏, 张菊. PD-1/PD-L1信号通路及其在胃癌治疗中的研究进展[J]. 现代医药卫生, 2020, 36(13): 2021-2025. doi: 10.3969/j.issn.1009-5519.2020.13.020

    TANG M, ZHANG J. PD-1/PD-L1 signaling pathway and its research progress in the treatment of gastric cancer[J]. Modern medicine and health, 2020, 36(13): 2021-2025 doi: 10.3969/j.issn.1009-5519.2020.13.020
    [17]
    WALK E E, YOHE S L, BECKMAN A, et al. The cancer immunotherapy biomarker testing landscape[J]. Arch Pathol Lab Med, 2020, 144(6): 706-724. doi: 10.5858/arpa.2018-0584-CP
    [18]
    王钎钎, 郑松. 抗血管生成联合免疫检查点抑制剂在晚期胃癌治疗中的研究进展[J]. 浙江中西医结合杂志, 2021, 31(7): 687-690. https://www.cnki.com.cn/Article/CJFDTOTAL-ZJZH202107033.htm

    WANG Q Q, ZHENG S. Progress in antiangiogenic combined immune checkpoint inhibitors in the treatment of advanced gastric cancer[J]. Zhejiang Journal of Integrated Traditional Chinese Med and Western Med, 2021, 31(7): 687-690. https://www.cnki.com.cn/Article/CJFDTOTAL-ZJZH202107033.htm
    [19]
    ABDEL-RAHMAN O. Prognostic impact of baseline quality of life status among patients with advanced gastric cancer; results from two randomized studies[J]. Expert Rev Pharmacoecon Outcomes Res, 2019, 19(6): 711-715.
    [20]
    TAKASHIMA A, SHITARA K, FAJITANI K, et al. Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase Ⅲ ABSOLUTE trial[J]. Gastric Cancer, 2019, 22(1): 155-163.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (92) PDF downloads(0) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return